First-in-Human(FIH)Trialat36Months: PhaseI/IITrialat3Months: 37% and 36% reduction in mean IOP with 98% and 96% of patients off topical IOP-lowering drops in 78 mcg and 39 mcg dose groups, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results